Heparins for prolif erative nephritides?

Nephron

Volumn 73, Issue 4, 1996, Pages 515-519

  Wardle, E N ^a  

^a NONE   (United Kingdom)

Author keywords

Glycosaminoglycans; Growth factors; Heparin; Low molecular weight heparins; Pentosan polysulphate; Proliferative glomerulonephritis; Thrombin

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE; PENTOSAN POLYSULFATE;

ENDOTHELIUM CELL; LEUKOCYTE; MESANGIUM CELL; PHAGOCYTE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; SHORT SURVEY; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTICOAGULANTS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPARIN; HUMANS;

EID: 0029774772     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189133     Document Type: Article

References (85)

1. Siifvcrskiold BP: Heparin and experimental glomerulonephritis. Skand Arch Physiol 1940; 83:175-179.
2. KJcincrman J: Effects of heparin on experimental nephritis in rabbits. I., ab Invest 1954:3: 495-500.
3. Good RA. Thomas L: Studies on the generalised Shartzman reaction. IV. Prevention of the local and generalised Shwartzman reactions with heparin. J Exp Med 1953:97:871-878.
4. Halpern B, Millicz P. Lagrue G: Protective action of heparin in experimental immune nephritis. Nature 1965;205:257-259.
5. Striker LJ. Peter EP. Elliot SJ. Doi T. Striker GE: Mesangial cell turnover: Effect of heparin and peptide growth factors. I., ab Invest 1991; 64:446-456.
6. Floege J. Eng E. Young BA. Couser WG. Johnson RJ: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioprolifcrativc glomerulonephritis. Kidney Int 1993;43:369-380.
7. Olson JL: Role of heparin as a protective agent following reduction of renal mass. Kidney Int 1984;25:376-382.
8. Ichikawa I, Yoshida Y. Fogo A. Purkcrson ML, Klahr S: Effect of heparin on the glomerular structure and function of remnant nephrons. Kidney Int 1988;34:638-644.
9. Wardle EN, Uldall P: The effects of heparin in patients with accelerated hypertension, progressive nephritis and renal allografts. Br Med J 1972;4:135-139.
10. Wardle EN. Uldall PR: Radiofibrinogen catabolism for detection of rejection in renal transplant recipients. Transplantation 1974:18: 508-517.
11. Naparstcck Y. Ben-Yehuda A. Madoio MP. et al: Binding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL-lpr/lpr mice by heparin. Arthritis Rheum 1990:33: 1554-1559.
12. Sai P. Pogu S. Ovary M: Heparin attenuates low dose streptozotocin induced immune diabetes in mice and inhibits the beta cell binding ofT splenocvtes in vitro. Diabctologia 1991: 24:212-217.
13. Lider O. Baharau H, Mekari YA: Suppression of experimental autoimmune disease and prolongation of allograft survival by treatment of animals with low doses of heparin. J Clin Invest 1989:83:752-757.
14. Nelson RM, Cecconi O, Roberts WG. Aruffo O. Linhardt RJ. Bevilacqua MP: Heparin oligosaccharides bind L-and P-sclectin and inhibit acute inflammation. Blood 1993:82:3253-3258.
15. Lev K. Cerrito M. Arfors KE: Sulfated polysaccharides inhibit rolling in rabbit mesentery venules. Am J Physiol 1991;260:H1667-1673.
16. Dziarski R: Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol 1989;143:356-365.
17. Hanahoe TH. Jones DR: Heparin and acute inflammation in the rat. Int Arch Allergy Appl Immunol 1988:86:243-244.
18. Schwarting GA. Gajewski A: Heparin inhibits specific glycosyl-transfcrase activities on interleukin 2 activated murine T cells. Biosci Rep 1988:8:389-399.
19. Ekre H, Naparstcck Y. Lider O, Hyden P, Hägermark O, Nilsson T. Vlodavsky I. Cohen I: Anti-inflammatory effects of heparin and its derivatives, inhibition of complement and of lymphocyte migration. Adv Exp Med Biol 1992;313:329-334.
20. Strunk K, Colten HR: Inhibition of the enzymatic activity of the first component of complement by heparin. Clin Immunol Immuno-pathol 1976:6:248-255.
21. Kazatchkine MD. Fearon DT. Silber JE. Austen KF: Surface associated heparin inhibits zymosan induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins. J Exp Med 1979:150:1202-1215.
22. Kilgare KS. Slten JP. Miller BF, Ward PA: Enhancement by the complement membrane attack complex of TNF-alpha induced endothelial cell expression of E-sclectin and ICAM-1. J Immunol 1995;155:1434-1441.
23. Leung L, Saigo K. Grant D: Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Blood 1989;73:177-184.
24. Tsubai I: A heparin related glycosaminoglycan inhibits Superoxide generation by neutrophils. Jpn J Inflam 1988;8:131-135.
25. Ferrer-Lopcz P. Renesto P. Prevost MC, Gou-nan P. Chinard M: Heparin inhibits neutrophil-induced platelet activation via cathcpsin G. J Lab Clin Med 1992;119:231-239.
26. West BC. Dunphy CH. Moore CA: Human neutrophil N-acetyl-?-D-glucosaminidase: Heparin inhibition. Biochem Med 1983:29:1-13.
27. Walsh RL. Dillon TJ, Scicchitano R. McLennan H: Heparin and heparan sulphate inhibitors of human leukocyte clastase. Clin Sci 1991; 81:341-346.
28. Lapenna D, Mezzctti A, De Gioia S, Ciofani G. Marzio L, Di Ilio G. Cuccuullo F: Heparin: Does it act as an antioxidant in vivo? Biochem Pharmacol 1992:44:188-191.
29. Karlsson J. Marklund L: Heparin-induced release of extracellular superoxide dismutase to human blood plasma. Biochem J 1987,242:55-59.
30. Wright TC, Castellot JJ. Diamond JR. Karnovsky MJ: Regulation of cellular proliferation by heparin and heparan sulphate; in Lane DA. Lindhai U (eds): Heparin. London. Arnold. 1989, pp 295-316.
31. Reilly CF. Kindy MS, Brown KE, Rosenberg RD: Heparin prevents vascular smooth muscle progression through the G1 phase of the cell cycle. J Bio I Chem 1989:264:6990-6995.
32. Smith CD. Wen D. Mooberry SL. Chang K-J: Inhibition of phosphatidyl-inositol-4-phos-phatc by heparin. Biochem J 1992,281:803-808.
33. McCaffrey TA. Falcone DF. Brayton CF. Agarwal LA: TGF-beta activity is potentiated by heparin via dissociation of the TGF-beta-u;-macroglobulin inactive complex. J Cell Biol 1989;109:441-448.
34. Lindner V, Olson NE, Clowes AW. Reid MA: Inhibition of smooth muscle cell proliferation in injured rat arteries. J Clin Invest 1992:90: 2044-2049.
35. Imai T, Hirata Y, Emori T. Marumo F: Heparin has an inhibitory effect on endothelin 1 synthesis and release by endothelial cells. Hypertension 1993:21:353-358.
36. Yokokawa K, Tahara H. Kohno M. Mandal AK. Yanagisawa M. Takeda T: Heparin regulates endothelin production through endothelium derived nitric oxide in human endothelial cells. J Clin Invest 1993:92:2080-2085.
37. Vasdeu S. Prabhakaran V. Sampson CA: Heparin lowers blood pressure and vascular calcium uptake in hypertensive rats. Scand J Clin Lab Invest 1991:51:321-328.
38. Coffey AK, Kamovsky MJ: Heparin inhibits mcsangial cell proliferation in Habu venom induced glomerular injury. Am J Pathol 1985: 120:248-255.
39. Tang WW. Wilson CB: Heparin decreases mcsangial cell matrix accumulation after selective antibody induced mcsangial cell injury. J Am Soc Nephrol 1992;3:921-929.
40. Diamond JR, Kamovsky MJ: Non-anticoagulant protective effect of heparin in chronic ami-nonucleoside nephrosis. Renal Physiol 1986;9: 366-374.
41. Ruoslahti E: Proteoglycans in cell regulation. J Biol Chem 1989:264:13369-13372.
42. Templeton DM: Proteoglycans in cell regulation. Clin Lab Sei 1992;29:141-166.
43. Hiebert LM. Liu JM: Heparin protects cultured arterial endothelial cells from damage by toxic oxygen radicals. Atherosclerosis 1990:83: 47-51.
44. Weiler JM. Edens RE. Linhardt RJ, Kapelonski DP: Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992:148:3210-3215.
45. Caughntann GB. Boachic RJ, Vesely JA: Postulated mechanism for heparin’s potentiation of Cl inhibitor function. Mol Immunol 1982; 19: 287-291.
46. Bartlett MR. Cowden WB. Parish CR: Differential effects of the anti-inflammatory compounds heparin, mannose-6-phosphate and castar., ospermine on degradation of the vascular basement membrane by leukocytes, endothelial cells and platelets. J Lab Clin Med 1995: 57:207-213.
47. Kenagy RD. Nikkari ST. Welgus HG. Clowes AW: Heparin inhibits the induction of three matrix metalloproteinases in primate arterial smooth muscle cells. J Clin Invest 1994:93: 1987-1993.
48. Maross Y: Interaction of chymotrypsin and clastase like enzymes of the human granulocyte with glycosaminoglycans. Biochim Biophys Acta 1981:659:351-361.
49. Brestd EP. McClain EJ: A mechanism for inhibition of luminol dependent neutrophil chemi-luminesccnce by polyanions. J Immunol 1983; 131:2515-2519.
50. Herbert JM. Maffrand JP: Effect of pentosan polysulphate, standard heparin and related compounds on protein kinase C activity. Biochim Biophys Acta 1991;1091:432-441.
51. Matzner Y, Marx G. Drexter RE. Eldor A: Inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thrornb Haemost 1984:52:134-137.
52. Pasini FL, Pasqoi A, Ceccatelli L. Orrico A, DiPerri T: Heparin inhibition of PMN leukocyte activation in vitro. Thrornb Res 1984:35: 527-537.
53. Mavier P. Prcaux AM, Rosenbaum J, Zafrani AS, Dhunteaux D: Toxicity of polymorphonuclear neutrophils against hepatocytes: Protective effect of heparin. Biochem Pharmacol 1989:38:1865-1867.
54. Rajtar G, Marchi E, de Gaetano G. Cerletti C: Effects of GAGs on platelet and leucocyte function: Role of N-sulfation. Biochem Pharmacol 1993;46:958-996.
55. Bazzani G. Nunez AB. Mascellani G. Bina-chini P. Dcjana E, del Mashio A: Effect of heparin. dcrmatan sulfate and related oligoderiva-tives on human PMN leucocyte functions. J Lab Clin Med 1993;121:268-272.
56. Leung L, Saigo K. Grant D: Heparin binds to monocytes and modulates their procoagulant activities and secretory phenotypes. Blood 1989:73:177-184.
57. Hirsh J: Heparin. N Engl J Med 1991:324: 1565-1574.
58. Asselot-Chapel C. Kern P. Labta-Robert J: Biosynthesis of interstitial collagens and fibronec-tin by porcine aortic smooth muscle cells. Biochim Biophys Acta 1989:993:240-244.
59. Hurley MM, Kream BE. Raisz LG: Structural determinants of capacity of heparin to inhibit collagen synthesis is 21-day rat calvariae. J BoneMinerRes 1990;5:1127-1133.
60. Zaragossa R. Battle-Tracev KM, Owen NE: Heparin inhibits sodium-hydrogen exchange in vascular smooth muscle cells. Am J Physiol 1990;258:C46-C53.
61. Ghosh TK. Eis PS, Mullaney JM. Ebert CL. Gill DL: Competitive reversible and potent antagonism of inositol 1.,4.,5-triphosphate-acti-vatcd calcium release by heparin. J Biol Chem 1988;263:11705-11709.
62. Smith CD. Wen D. Moobcrry SL. Chang KJ: Inhibition of phosphatidyI-inositol-4-phos-phatc kinase by heparin: A possible mechanism for the antiproliferative effects of heparin. Bio-chemJ 1992:281:802-808.
63. Wright TC. Pukac LA. Castellot JJ. et al: Heparin suppresses the induction of c-fos and c-myc messenger RNA in murine fibroblasts by selective inhibition of a protein kinase C dependent pathway. Proc Natl Acad Sci USA 1989; 86:3199-3202.
64. Groggel GC. Marindes GM, Hovinge P. Hammond E, Linker A: Inhibition of rat mesangial cell growth by heparan sulphate. Am J Physiol 1990;258:F259-F265.
65. Castellot H. Hoover RL, Harper PA. Kamovs-ky MJ: Heparin and glomerular epithelial cell secreted heparin-like species inhibit mesangial cell proliferation. Am J Pathol 1985; 120:427-435.
66. Caenazzo C, Garbisa S, Ccol M, Baggio B. Bor-satti A, Marchi E. Gambaro G: Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: Molecular clues for its activity in nephropathy. Nephrol Dial Transplant 1995:10:175-184.
67. Tiozzo R. Cingi MR. Reggiani D. Andrcoli T, Calandra S, Milani MR. Piani S. Marchi E. Barbanti M: Effect of the desulfatation of heparin on its anticoagulant and anti-proliferative activity. Thromb Res 1993;70:99-106.
68. Mattana J, Singhal PS: Heparin attenuates the efect of mitogenic vasoconstrictors on mesangial cell proliferation and handling of immunoglobulin G complexes. J Pharmacol Exp Ther 1995;273:80-87.
69. Furness PN. Drakeiy S: Heparin causes partial removal of glomerular antigen deposits by a mechanism independent of its anticoagulant properties. J Pathol 1992:168:217-220.
70. Cade JR. DcQuasada AM. Shires DL, Levin DM. Hacketl RL. Spooner GR. Schlein EM. Pickering MJ. Holcomb A: The effect of longterm high dose heparin treatment on the course of chronic proliferative glomerulonephritis. Nephron 1971;8:67-80.
71. Arieff AI. Pingerra WF: Rapidly progressive glomerulonephritis treated with anticoagulants. Arch Intern Med 1972;129:77-84.
72. KJahr S. Hcrfets M. Purkcrson ML: The influence of anticoagulalion on the progression of experimental renal disease; in Mitch WE. Brenner RM. Stein III (eds): The Progressive Nature of Renal Disease. New York, Churchill Livingstone. 1986.
73. Wardle EN: Glomerulopathies: Cell Biology and Immunology. London. Harwood Academic Publishers, 1996. pp 349-378.
74. Animal J. Bridery F, Wolf M: Antibodies to macromolecular PF4-heparin complexes in heparin induced thrombocytopenia. Thromb Haemost 1995;73:21-28.
75. Greinacher A, Michels I, Kiefel V, Mueiler-Eckardt CA: A rapid and sensitive test for diagnosing heparin associated thrombocytopenia. Thromb Haemost 1991;66:734-736.
76. Magnani HN: Heparin induced thrombocytopenia: An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70:554-561.
77. Krupinski K, Breddin HK. Casu B: Anticoagulant and antithrombotic effects of chemically modified heparins and pentosan polysulfate. Haemostasis 1990;20:81-92.
78. Warkentin TE. Levine ME. Hirsh J. Horse-wood P. Roberts RS. Gent M. Kellon JG: Hepariniaduced thrombocytopenia in patients treated with low MW heparin or unfractionated heparin. N Engl J Med 1995:332:1330-1335.
79. Wardle EN: Altering the course of proliferative nephritides. J lilt Med Res 1992:20:361-370.
80. Berthoux FC. Freyrier AM. Zech PY. Traegcr J: Activité anti-complémentaire d'un polyanion: le polyester sulfurique de pentosane. Pathol Biol (Paris) 1977;25:33-36.
81. Freyburger G. Larrue F. Manciet G: Hemo-rheological changes in elderly subjects. Effect of pentosan polysulfate and possible roleofleu-cocytc arachidonic acid metabolism. Thromb Haemost 1989;57:322-325.
82. Baici A. Salgam P. Fehr K, Boni A: Inhibition of human elastase release from polymorphonuclear leucocytes by gold sodium thiomalate and pentosan polvsulphate. Biochem Pharmacol 1981:30:703-708.
83. Delves U. Paul JE. Muller-Berghaus G: Effects of the heparinoid pentosan polysulphate (SP54)on the functional properties of cultured bovine aortic endothelial cells. Blut 1985:51: 127-136.
84. Herbert JM. Nuti D, Paul R. Maffrand JP: In vitro and ex vivo regulation of vascular smooth muscle cell growth and phenotypic modulation by sulphatcd polysaccharides. Artery 1988; 16: 1-14.
85. Zugmaicr G. Lippman ME, Wellstein A: Inhibition by pentosan polysulphate of heparin binding growth factors released from tumor cells. J Natl Cancer Inst 1992;84:1716-1724.